Hormone – Page 3 – Talk Bio

Actionable Insights Powered by AI

European Medicines Agency Investigates Potential Link Between Hair Loss Drugs and Suicidal Thoughts

10 months ago talkbio0Tagged Agencies, European (ethnic group), Feeling suicidal (finding), finasteride, Hair, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, psychiatric side effects

EMA, hair loss drugs, finasteride, dutasteride, suicidal thoughts, psychiatric side effects, European Medicines Agency

Theratechnologies Warns of Temporary Supply Disruption for EGRIFTA SV in Early 2025 Due to Third-Party Facility Shutdown

10 months ago talkbio0Tagged Disruption, Egrifta, Facility (object), HIV drug, shutdown, sievert, Theratechnologies

Theratechnologies, EGRIFTA SV, supply disruption, third-party facility shutdown, HIV drug, 2025

Novo Nordisk’s GLP-1 Agonist Demonstrates Significant BMI Reduction in Children Aged 6-12 in Phase 3 Trial

11 months ago talkbio0Tagged agonists, Body mass index procedure, Glucagon-Like Peptide 1, liraglutide, Nordisk, Obesity, Pediatric brand name, Phase 3 trial, semaglutide

GLP-1 agonists, obesity, weight loss, liraglutide, semaglutide, pediatric obesity, BMI reduction, Novo Nordisk, Phase 3 trial.

Lilly’s Weekly Insulin Candidate Efsitora Alfa Shows Promising Results in Phase III Trials

11 months ago talkbio0Tagged Alfa, Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, efsitora, Eli, Eli Lilly, Insulin, Phase 3 Clinical Trials, QWINT, Weekly

Eli Lilly, Efsitora Alfa, Weekly Insulin, Type 1 Diabetes, Type 2 Diabetes, Phase III Trials, QWINT Studies, Diabetes Treatment

EASD24: Lilly’s Weekly Insulin Efsitora Demonstrates Efficacy but Raises Hypoglycemia Concerns

11 months ago talkbio0Tagged Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, EASD24, efsitora, Eli, Eli Lilly, Hypoglycemia, Insulin, insulin therapy, Weekly

Eli Lilly, EASD24, Weekly Insulin, Efsitora, Type 1 Diabetes, Type 2 Diabetes, Hypoglycemia, Insulin Therapy

Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials

11 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Hemoglobin A1c measurement, Insulin, insulin therapy, non-inferiority, once-weekly, Phase 3 trials

Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.

Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials

11 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Insulin, insulin therapy, Phase 3 Clinical Trials, QWINT-1, QWINT-3, Weekly

Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management

England’s NICE Approves Theramex’s Uterine Fibroids Treatment

11 months ago talkbio0Tagged Antagonist muscle action, gonadorelin, hormonal add-back therapy, linzagolix, Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Theramex, Uterine Fibroids, women 's, Yselty

NICE, Theramex, uterine fibroids, linzagolix, Yselty, GnRH antagonist, hormonal add-back therapy, NHS, women’s health

Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection

12 months ago talkbio0Tagged Clinical Research, COMBINE-1, File (record), Icodec, IcoSema, Insulin, Nordisk, once-weekly, regulatory approval, semaglutide, United States Food and Drug Administration

Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval

Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns

12 months ago talkbio0Tagged Icodec, IcoSema, Insulin, Nordisk, once-weekly, Rejection (Psychology), semaglutide, United States Food and Drug Administration

Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema